Mirtazapinum [Inn-Latin] en es it fr

Mirtazapinum [Inn-Latin] Brand names, Mirtazapinum [Inn-Latin] Analogs

Mirtazapinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Mirtazapinum [Inn-Latin] Chemical_Formula


Mirtazapinum [Inn-Latin] RX_link


Mirtazapinum [Inn-Latin] fda sheet

Mirtazapinum_[Inn-Latin] FDA

Mirtazapinum [Inn-Latin] msds (material safety sheet)

Mirtazapinum_[Inn-Latin] MSDS

Mirtazapinum [Inn-Latin] Synthesis Reference

W. J. Van der Burg, U.S. Pat. 4,062,848 (1977)

Mirtazapinum [Inn-Latin] Molecular Weight

265.353 g/mol

Mirtazapinum [Inn-Latin] Melting Point


Mirtazapinum [Inn-Latin] H2O Solubility


Mirtazapinum [Inn-Latin] State


Mirtazapinum [Inn-Latin] LogP


Mirtazapinum [Inn-Latin] Dosage Forms

Tablet; Tablet (orally disintegrating)

Mirtazapinum [Inn-Latin] Indication

For the treatment of major depressive disorder.

Mirtazapinum [Inn-Latin] Pharmacology

Mirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.

Mirtazapinum [Inn-Latin] Absorption

Rapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.

Mirtazapinum [Inn-Latin] side effects and Toxicity

Symptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50=mg/kg (orally in rat).

Mirtazapinum [Inn-Latin] Patient Information

Mirtazapinum [Inn-Latin] Organisms Affected

Humans and other mammals